Endocan: A Biomarker for Hepatosteatosis in Patients with Metabolic Syndrome

Table 2

Correlation between endocan and characteristics in patients of NAFLD.

	Endocan
Age (years)
	0.309
	0.05
BMI (kg/m^2)
	-0.386
	0.015
HSI
	-0.223
	0.173
FLI
	-0.262
	0.112

NAFLD: nonalcoholic fatty liver disease; BMI: body mass index; HSI: hepatic steatosis index; FLI: fatty liver index.